
Earwax Secretions May Help Detect Parkinson's Disease
Researchers found that four volatile organic compounds (VOCs) in ear canal secretions significantly differed between participants with and without PD.
The compounds — ethylbenzene, 4-ethyltoluene, pentanal, and 2-pentadecyl-1,3-dioxolane — may represent potential biomarkers. An artificial intelligence olfactory (AIO)-based screening model used in the study identified those with PD with 94% accuracy.
'The accuracy of the model really surprised us,' study investigator Hao Dong, Research Center for Frontier Fundamental Studies, Zhejiang Lab, Hangzhou, China, MD, told Medscape Medical News .
However, the study was a 'small-scale, single-center experiment,' he noted in a press release.
'The next step is to conduct further research at different stages of the disease, in multiple research centers, and among multiple ethnic groups in order to determine whether this method has greater practical application value,' Dong said.
The findings were published online recently in Analytical Chemistry .
Unique Odor Profile
'Our team has long been engaged in the detection of [VOCs] secreted by the human body. By chance, we came across reports on the detection of sebum VOCs for Parkinson's,' Dong said.
Sebum, the oily substance secreted by the skin, may carry a distinct scent in individuals with PD. In a 2019 study cited by Dong, researchers noninvasively collected sebum samples from the upper backs of 64 participants. The findings suggested that samples from those with PD contained compounds associated with a unique odor profile.
Dong and his team began with a confirmatory experiment using sebum samples collected from the upper back, as in the original study. However, they found that earwax was easier to collect and had a more stable chemical composition. These findings led them to focus on earwax in the current study.
Ear wax also contains sebum. But unlike sebum on the surface of the skin, which is exposed to various factors that can degrade it. In contrast, sebum on skin inside the ear canal is protected.
Dong's study included 209 participants, 108 of whom had a diagnosis of PD. Ear canal secretions were collected from all participants using swabs and analyzed using gas chromatography-mass spectrometry.
Results showed that ear canal secretions from participants with PD contained 196 distinct VOCs compared with 168 VOCs in those without PD. Interestingly, no two participants had identical VOC profiles.
A Disease 'Fingerprint'?
'In this case, VOC components could be used as a 'fingerprint' for disease identification,' the researchers wrote.
Adjusted analyses identified four VOCs that significantly differed between participants with and without PD: ethylbenzene, 4-ethyltoluene, pentanal, and 2-pentadecyl-1,3-dioxolane.
The investigators trained the AIO system using VOC data. By combining gas chromatography-surface acoustic wave sensors with a convolutional neural network (CNN) model, the AIO system achieved up to 94.4% accuracy in distinguishing participants with PD from those without.
In addition, the CNN model demonstrated a high level of performance with an area under the curve of 0.98, well above the 0.8 threshold considered strong by the researchers.
'Further enhancements to the diagnostic model could pave the way for a promising new PD diagnostic solution and the clinical use of a bedside PD diagnostic device,' the investigators wrote.
For now, Dong said the study's takeaway message for clinicians is that 'the potential of volatile organic compounds secreted by the skin as biomarkers for Parkinson's disease has been further verified.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Geek Girl Authority
4 hours ago
- Geek Girl Authority
Welcome to the Chatsubo: Apple TV+'s NEUROMANCER Is Now in Production
Highlights Apple shared a brief teaser for its highly anticipated adaptation of Neuromancer , which you can watch below. Neuromancer The 10-episode first season goes into production on the same day as the publishing anniversary of William Gibson's award-winning sci-fi novel of the same name. Callum Turner leads the cast as Case, a hacker plunged into a world of espionage. Neuromancer Welcome to the Chatsubo, cowboy. Neuromancer is now in production. Apple shared a brief teaser to celebrate the beginning of the production process for the 10-episode first season. Adapted from William Gibson's award-winning sci-fi novel of the same name, July 1 also marks the 41st publishing anniversary. That's right: Neuromancer hit bookshelves on July 1, 1984. RELATED: The Mule Wreaks Havoc in Foundation Season 3 Trailer and New Photos The aforementioned teaser showcases the Chatsubo, a bar in Ninsei of Chiba City. It attracts a bevy of colorful underworld characters, from hackers and dealers to criminals. Ratz, a man with a prosthetic arm, usually tends bar. About the Series Here's a synopsis per Apple: 'BAFTA Award-nominee Callum Turner ( Masters of the Air ) will star in the new 10-episode drama that follows a damaged, top-rung super-hacker named Case who is thrust into a web of digital espionage and high stakes crime with his partner Molly (played by Briana Middleton), a razor-girl assassin with mirrored eyes aiming to pull a heist on a corporate dynasty with untold secrets.' RELATED: New TV Shows This Week (June 29 – July 5) The Cast and Crew In addition to Turner as Case and Middleton as Molly, the rest of the Neuromancer main cast includes Joseph Lee, Mark Strong, Cleménce Poésy, Peter Sarsgaard, Emma Laird, Dane DeHaan, André De Shields, Max Irons and Marc Menchaca. Graham Roland and J.D. Dillard are co-creators, while the former takes on the role of showrunner. Dillard will be at the helm for the pilot episode. Roland and Dillard will also executive produce alongside David Ellison, Dana Goldberg and Matt Thunell for Skydance Television; Anonymous Content; Drake, Adel 'Future' Nur and Jason Shrier for DreamCrew Entertainment; and Zack Hayden and William Gibson. In Production Neuromancer will premiere on Apple TV+. As of writing, we don't have a release date. Before you go, check out the 'In Production' teaser below. On Location: The Lighterman in Apple TV+'s SLOW HORSES Contact: [email protected] What I do: I'm GGA's Managing Editor, a Senior Contributor, and Press Coordinator. I manage, contribute, and coordinate. Sometimes all at once. Joking aside, I oversee day-to-day operations for GGA, write, edit, and assess interview opportunities/press events. Who I am: Before moving to Los Angeles after studying theater in college, I was born and raised in Amish country, Ohio. No, I am not Amish, even if I sometimes sport a modest bonnet. Bylines in: Tell-Tale TV, Culturess, Sideshow Collectibles, and inkMend on Medium. Critic: Rotten Tomatoes, CherryPicks, and the Hollywood Creative Alliance.

Entrepreneur
11 hours ago
- Entrepreneur
How One Founder Is Rethinking Supplements With David Beckham
5 lessons on how to bring trust and transparency into a controversial industry. Opinions expressed by Entrepreneur contributors are their own. When Danny Yeung sat down for dinner with soccer legend David Beckham, there was no agenda. No pitch deck. Just two guys talking health. They met through a mutual friend in Hong Kong. Yeung, the CEO of Prenetics, a health tech company specializing in genomics and diagnostics, wanted to create a wellness brand rooted in science. Beckham wanted a product he could take every day without juggling a shelf full of pills. That conversation led to the creation of IM8, a supplement powder designed to support energy, gut health, immunity, and focus. In five months, it has shipped more than 3 million servings to customers in 31 countries. The growth has been sizeable. In its first full quarter of sales, IM8 generated $5.7 million in revenue, helping Prenetics raise its full-year forecast to between $80 and $100 million. Beckham's endorsement helped, of course. But Yeung says the goal wasn't just to put a famous face on the box. It was to create something the founder and the athlete would both want to use. Beckham takes the product daily. His kids take it. His parents do, too. "If this product didn't work, David wouldn't use it—and neither would I," Yeung says. "We built it for ourselves first. Everything else came after." Here's what Yeung learned in building the company. Lesson 1: Start with science Yeung says the vast majority of supplement companies work backward—designing the brand first and then sourcing ingredients to fit a specific price point. "They lead with a logo and build the formula later," he says. "That's not how it should work." IM8 reversed the process. Before a single package was designed, the company spent over a year developing the formula with scientists and doctors, many of whom had never partnered with a supplement brand before. "We approached it like a biotech company," Yeung says. "We had real clinical trials, real data. No fluff." Related: The Supplement Business Has a Trust Problem. This Tech Startup Wants to Fix That. Lesson 2: Transparency isn't optional With more than 200,000 supplements on the market and little federal oversight, many consumers are understandably skeptical. "You can sell dust and call it protein. That's legal. That's the reality," says Yeung. IM8 tries to counter that with full transparency. The formula includes over 90 ingredients, including CoQ10, prebiotics, probiotics, and postbiotics. It's NSF Certified for Sport. Lab test results are published online. And the company publicly names its manufacturing partner. Lesson 3: Keep it simple Beckham wanted fewer pills in his daily routine. The idea behind IM8's Daily Ultimate Essentials was to simplify supplementation: one scoop, once a day, covering multiple health needs. The brand has plans to expand, but only with a few highly vetted products per year. Yeung emphasizes quality over speed. "We're not a company that wants to launch 50 different products. We want to focus on doing a few things very well. If we don't think something is best in class, we won't do it." Yeung's taking that same mindset to the business side. Prenetics is in active discussions with crypto industry veterans to integrate Bitcoin into its treasury strategy. Related: Inside The New Era of Longevity Supplements Lesson 4: A celebrity partner can't fix a bad product Yeung says too many founders look for celebrity partners to grab attention, not to build staying power. "I didn't want to be just another celebrity brand. We've seen too many of those," he says. That's why he didn't pitch Beckham on a business. They met over dinner. Talked science. Swapped health routines. "It wasn't a transaction," Yeung says. "It was two people figuring out if they believed in the same thing." Yeung believes Beckham didn't just join because of a business opportunity, but because he believed in the science. He has been involved in the process, reviewing product iterations, offering feedback on packaging, and flagging early customer reactions. Lesson 5: Trust has to be earned You can put a famous face on your brand, but if it doesn't work, you're not going to last. "People know when something's real," he says. "You can't fake that." Yeung calls IM8 a "trust product." Customers are putting it in their bodies every day, and that responsibility shapes how the business operates. The brand's 12-week clinical study showed that 95% of participants reported feeling more energized. Customer retention is strong. And feedback, Yeung says, has been more meaningful than any marketing metric. "If people are putting this in their bodies every day, you better get it right." Related: Trust Is a Business Metric Now. Here's How Leaders Can Earn It.
Yahoo
17 hours ago
- Yahoo
Amgen and Zai Lab's trial of gastric cancer therapy meets primary endpoint
Amgen and Zai Lab have reported that the Phase III FORTITUDE-101 trial, assessing bemarituzumab in combination with chemotherapy (mFOLFOX6), achieved its primary goal of overall survival (OS) in individuals with unresectable locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) cancer. The combo showed OS improvement against placebo with chemotherapy in G/GEJ patients with fibroblast growth factor receptor 2b (FGFR2b) overexpression, defined as 2+/3+ staining in at least 10% of tumour cells, as well as those who are non-human epidermal growth factor receptor 2 (HER2) positive. The placebo-controlled, randomised, double-blind trial involved 547 subjects across 300 sites in 37 nations. It was designed to assess the combo as a first-line treatment for this patient group. Its primary outcome measure is OS in those with FGFR2b ≥10% 2+/3+ tumour cell staining. Key secondary outcome measures are overall response rate (ORR) and progression-free survival (PFS). Notably, the trial incorporated more extensive ocular-related monitoring than earlier bemarituzumab trials. Zai Lab, which holds joint development and commercialisation rights for the therapy in mainland China, Macau, Taiwan, and Hong Kong, supported the conduct of the FORTITUDE-101 trial. Bemarituzumab has also received breakthrough therapy designation from the China Center for Drug Evaluation for treating FGFR2b-positive gastric and gastroesophageal junction adenocarcinoma. In addition to FORTITUDE-101, a Phase III trial of bemarituzumab with chemotherapy and nivolumab is underway for the first-line gastric cancer treatment, with data readout expected in the second half of 2025. Amgen research and development executive vice-president Jay Bradner said: "Most patients with gastric cancer are diagnosed at an advanced stage, with poor prognosis, low survival rates, and limited therapeutic options. "These first positive top-line results of an FGFR2b targeted monoclonal antibody from our Phase III FORTITUDE-101 study mark a meaningful advance in the development of effective targeted therapy for gastric cancer." "Amgen and Zai Lab's trial of gastric cancer therapy meets primary endpoint" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.